Indo National Ltd (NIPPOBATRY)

Capital Goods · Dry cells · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹329 ↓ 31.19% (1Y)

🎯 Key Takeaways

Indo-National Ltd is undergoing a strategic pivot from traditional capital goods manufacturing to high-growth defence electronics and medical equipment sectors, marked by recent acquisitions in Aidin Technologies and Medcuore Medical Solutions. Despite stable revenue trends, the company has seen a sharp deterioration in profitability, with ROE and ROCE turning deeply negative and quarterly losses widening, indicating execution or margin pressures in its core operations.
Revenue grew 8.4% QoQ to ₹116 in Q1FY27.
⚠️ 1) Persistent profitability weakness despite revenue stability, with operating losses widening and margins turning deeply negative, signaling potentia

Market Cap

₹247

P/B Ratio

0.56

ROE

-5.9%

ROCE

-5.7%

Debt/Equity

0.12

Div Yield

1.14%

Promoter

65.3%

✨ Ask AI About NIPPOBATRY 📊 Interactive Charts

📖 The Story

Indo-National Ltd is undergoing a strategic pivot from traditional capital goods manufacturing to high-growth defence electronics and medical equipment sectors, marked by recent acquisitions in Aidin Technologies and Medcuore Medical Solutions. Despite stable revenue trends, the company has seen a sharp deterioration in profitability, with ROE and ROCE turning deeply negative and quarterly losses widening, indicating execution or margin pressures in its core operations.

📰 What's Happening

In July 2026, the company acquired a 31.82% stake in Aidin Technologies Private Limited for Rs. 34.99 crore to enter the defence electronics sector, citing a 12-14% CAGR in India's Rs. 25,000 crore market. This was followed by an additional investment of Rs. 99.88 lakhs in May 2026 to raise its stake in Medcuore Medical Solutions to 59.16%, expanding into air purifiers and medical equipment. Management views these moves as diversification plays to offset weakness in traditional segments and enhance long-term profitability.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	119	120	106	107	116
Operating Profit	-0	1	-10	-21	-3
OPM %	-0.3%	0.6%	-9.5%	-20.0%	-2.8%
Net Profit	1	1	-8	-21	2
EPS	₹1.36	₹1.85	₹-10.46	₹-27.87	₹2.85

Quarterly financials reveal a troubling trend: revenue has remained relatively flat over the past year, but operating performance has deteriorated significantly, with operating losses expanding from Rs. 10 lakh in December 2025 to Rs. 21 lakh in March 2026. This contrasts with earlier quarters where small profits were recorded, suggesting deteriorating margins or cost inflation. The sharp drop in net profit — from Rs. 1 crore in September 2025 to a loss of Rs. 21 lakh in March 2026 — reflects mounting pressure despite stable top-line performance.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on profitability or growth targets in the latest financial results filing (August 14, 2026), merely acknowledging the AGM and auditor review. However, prior announcements indicate strategic intent to leverage acquisitions for long-term diversification and profitability, particularly in defence and medical segments. The lack of near-term guidance suggests uncertainty about near-term earnings recovery.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	4	4	4	4
Reserves	446	434	394	299
Borrowings	37	53	41	34
Total Liabilities	719	721	569	431
Fixed Assets	188	223	141	155
Investments	129	96	154	61
Total Assets	719	721	569	431

The balance sheet shows a significant drawdown in equity and reserves, with equity declining from Rs. 4 crore to Rs. 4 crore but reserves falling sharply from Rs. 394 crore to Rs. 299 crore between March 2025 and March 2026, while borrowings rose from Rs. 41 crore to Rs. 34 crore. Total assets also declined from Rs. 721 crore to Rs. 569 crore to Rs. 431 crore, indicating asset reduction or reclassification. The company maintains a very low debt ratio (D/E of 0.12), but the erosion in equity and reserves raises concerns about capital resilience amid ongoing investments.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-56
Investing	+80
Financing	-19
Net Cash Flow	+6

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	65.3%	65.3%	65.3%	65.3%
FII	0.0%	0.0%	0.0%	0.0%
DII	0.0%	0.0%	0.0%	0.0%
Public	29.3%	29.3%	29.2%	29.2%
# Shareholders	13,993	13,855	13,958	14,297

Promoter holding remains stable at 65.35% over the last four quarters, with no FII or DII holdings reported in recent filings. The public shareholding base has slightly increased, from 29.24% to 29.28%, with the number of shareholders rising from 13,958 to 14,297. There are no signs of institutional accumulation or exit, and no promoter pledging has been disclosed. The shareholder base remains retail-heavy and concentrated.

⚖️ Peer Comparison — Dry cells

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
EVEREADY	2,370	13.3	24.7%	28.6%	0.29
NIPPOBATRY	247	—	-5.7%	-5.9%	0.12
LAKHNNATNL	196	45.6	6.2%	4.0%	0.00
ATCENERGY	—	—	—	—	0.34

🔗 Peer Stock Analyses

EVEREADY LAKHNNATNL ATCENERGY

⚠️ Risk Factors

1) Persistent profitability weakness despite revenue stability, with operating losses widening and margins turning deeply negative, signaling potential structural or cost-related challenges. 2) Capital is being deployed into strategic acquisitions, but these have not yet translated into improved financial performance, raising concerns about integration risks and ROI. 3) The company's financial resilience appears constrained by declining reserves and asset base, even as it funds new investments, potentially straining liquidity if losses persist.

📋 Recent Filings

🧠 Analyst's Read

Indo-National is in a strategic transition phase, betting on defence and medical electronics to drive future growth, but current financial performance reflects significant headwinds in its core operations. Investors should monitor whether the acquired businesses begin contributing positively to earnings and whether margin recovery can materialize in the next 12-18 months.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on NIPPOBATRY

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NIPPOBATRY files new disclosures

Track NIPPOBATRY filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NIPPOBATRY — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd